Single-day therapy: an expert opinion on a recent development for the episodic treatment of recurrent genital herpes

Authors

  • Стівен Тайєрін University of Texas Health Science Center, United States
  • Камал Хамед Transplantation and Immunology Unit, Novartis, East Hanover, United States
  • Гарі Річвалд Los Angeles, C, United States

DOI:

https://doi.org/10.18370/2309-4117.2013.9.92-94

Keywords:

single-day Famciclovir, genital herpes, patient-initiated episodic therapy

Abstract

One common method for treating recurrent genital herpes outbreaks is 3-5 day episodic therapy with nucleoside analogues. However, since maximum viral replication occurs within 24 h after the onset of symptoms, short-term patient-initiated episodic therapy started at prodromal onset or at the first appearance of lesions in patients without a prodrome may represent an important option. In a recent randomized trial, single-day Famciclovir treatment decreased lesion healing time and the duration of pain and other symptoms by approximately 2 days compared to placebo, and prevented progression to a full outbreak in almost one in four patients. 

Author Biographies

Стівен Тайєрін, University of Texas Health Science Center

Department of Dermatology, Microbiology and Molecular Genetics and Internal Medicine

Камал Хамед, Transplantation and Immunology Unit, Novartis, East Hanover

Infectious Diseases

References

  1. ACOG Committee on Practice Bulletins – Gynecology (2004) Obstet Gynecol 104(5 pt 1):1111-1118.
  2. Aoki FY, Tyring S, Mitoma-Diaz F, Gross G, Gao J, Hamed K (2006) Single-day, patientinitiated famciclovir therapy for recurrent genital herpes: a randomized, double blind, placebo-controlled trial. Clin Infect Dis 42:8-13.
  3. Brown ZA, Kern ER, Spruance SL, Overall JC Jr (1979) Clinical and virologic course of herpes simplex genitalis. West J Med 130:414-421.
  4. Corey L, Wald A, Patel R, Sacks SL, Tyring SK, Warren T et al. (2004) Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 350:11-20.
  5. Diaz-Mitoma F, Sibbald G, Shafran SD, Boon R, Saltzman RL (1998) Oral famciclovir for the suppression of recurrent genital herpes: a randomized controlled trial. JAMA 280:887-892.
  6. Drob S, Loemer M, Lifshutz H (1985) Genital herpes: the psychological consequences. Br J Med Psychol 58 (Pt 4):307315.
  7. Fleming DT, McQuillan GM, Johnson RE et al. (1997) Herpes simplex virus type 2 in the United States, 1976-1994. N Engl J Med 337:1105-1111.
  8. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ (2006) Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 20:73-83.
  9. Leone PA, Trottier S, Miller JM (2002) Valacyclovir for episodic treatment of genital herpes: a shorter 3-day treatment course compared with 5-day treatment. Clin Infect Dis 34:958-962.
  10. Malkin JE (2004) Epidemiology of genital herpes simplex virus infection in developed countries. Herpes 11(suppl 1):2A-23A.
  11. Pue MA, Benet MA (1993) Pharmacokinetics of famciclovir in man. Antivir Chem Chemother 4(suppl 1):47-55.
  12. Reichman RC, Badger GJ, Guinan ME, Nahmias AJ, Keeney RE, Davis LG et al. (1983) Topically administered acyclovir in the treatment of recurrent herpes simplex genitalis: a controlled trial. J Infect Dis 147:336-340.
  13. Reichman RC, Badger GJ, Mertz GJ, Corey L, Richman DD, Connor JD et al. (1984) Treatment of recurrent genital her-pes simplex infections with oral acyclovir. A controlled trial. JAMA 251:2103-2107.
  14. Reitano M, Tyring S, Lang W, Thoming C, Worm AM, Borelli S et al. (1998) Valaciclovir for the suppression of recurent genital herpes simplex virus infection: a large-scale dose range-Wnding study. J Infect Dis 178:603-610.
  15. Sacks SL, Aoki FY, Diaz-Mitoma F, Sellors J, Shafran SD (1996) Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes. JAMA 276:44-49.
  16. Spruance SL (1995) Herpes simplex labialis. In: Sacks SL, Straus SE, Whitley RJ, et al. (eds). Clinical management of herpes viruses. IOS Press, Amsterdam, pp 3-42.
  17. Spruance SL, Wenerstrom G (1984) Pathogenesis of recur-rent herpes simplex labialis. IV. Maturation of lesions within 8 hours after onset and implications for antiviral treatment. Oral Surg Oral Med Oral Pathol 58:667-671.
  18. Tyring SK, Douglas JM Jr, Corey L, Spruance SL, Esmann J (1998) A randomized, placebo-controlled comparison of oral valacyclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections. The Valaciclovir In ternational Study Group. Arch Dermatol 134:185-191.
  19. Wald A, Carrell D, Remington M, Kexel E, Zeh J, Corey L (2002) Two-day regimen of acyclovir for treatment of re curent genital herpes simplex virus type 2 infection. Clin In fect Dis 34:944-948.
  20. Whitley RJ, Kimberlin DW, Roizman B (1998) Herpes simplex viruses. Clin Infect Dis 26:541-55.

Downloads

Published

2013-11-14

How to Cite

Тайєрін, С., Хамед, К., & Річвалд, Г. (2013). Single-day therapy: an expert opinion on a recent development for the episodic treatment of recurrent genital herpes. REPRODUCTIVE ENDOCRINOLOGY, (9), 92–94. https://doi.org/10.18370/2309-4117.2013.9.92-94

Issue

No. 9 (2013)

Section

Inflammatory diseases

License

Copyright (c) 2014 Стівен Тайєрін, Камал Хамед, Гарі Річвалд

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.